Eran Ovadya, Chief Financial Officer of NurExone stated, "The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Highlights,Sumitomo Mitsui Trust Group Inc. increased its holdings in Nurix Therapeutics by 42.7% in Q4.,Various firms have ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Exelixis (EXEL – Research Report), with a price ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...